Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker’s ...

Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Omvoh has possible interactions with certain vaccines. Examples include the chickenpox vaccine and the nasal spray flu vaccine (FluMist). Talk with your doctor to avoid potentially harmful effects ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly's Q4 revenue surged 45% to $13.53 billion, fueled by Mounjaro and Zepbound. 2025 guidance forecasts up to $61 ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid momentum. The company's adjusted earnings per share are exp ...

B, consensus $58.91B. The company said, “The company anticipates 2025 revenue to be between $58.0 billion and $61.0 ...